Response-guided neoadjuvant chemotherapy for breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 29, 2013, Pages 3623-3630

  Von Minckwitz, Gunter ^a,k   Blohmer, Jens Uwe ^b   Costa, Serban Dan ^c   Denkert, Carsten ^d   Eidtmann, Holger ^e   Eiermann, Wolfgang ^f   Gerber, Bernd ^g   Hanusch, Claus ^f   Hilfrich, Jörn ^h   Huober, Jens ^i,q   Jackisch, Christian ^j   Kaufmann, Manfred ^r   Kümmel, Sherko ^l   Paepke, Stefan ^m   Schneeweiss, Andreas ⁿ   Untch, Michael ^o   Zahm, Dirk Michael ^p   Mehta, Keyur ^a   Loibl, Sibylle ^a,j  

^a GBG Forschungs GmbH   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Klinikum Zum Roten Kreuz   (Germany)

^g ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^h Henrietten Stiftung   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j Klinikum Offenbach GmbH   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l UNIVERSITY HOSPITAL ESSEN   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o Helios Klinikum   (Germany)

^p Brustzentrum Stiftung Rehabilitation Heidelberg   (Germany)

^q CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FOLLOW UP; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; LONG TERM SURVIVAL; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREOPERATIVE CHEMOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL PREDICTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; BREAST NEOPLASMS; CHEMISTRY; FEMALE; MORTALITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2;

EID: 84882977388     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.0940     Document Type: Conference Paper

References (23)

1. Huober J, von Minckwitz G, Denkert C, et al: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat 124:133-140, 2010
2. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785, 2008 [Erratum: J Clin Oncol 26:2793, 2008]
3. Khayat D, Antoine EC, Nizri D, et al: Neoadjuvant chemotherapy in breast cancer: Simple prognostic, or useful predictive factor? Am Soc Clin Oncol Ed Book 510-515, 2001
4. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
5. Heys SD, Hutcheon AW, Sarkar TK, et al: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3:S69-S74, 2002 (suppl 2)
6. Zelek L, Barthier S, Riofrio M, et al: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267-2272, 2001
7. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227-1233, 2003
8. Welt A, von Minckwitz G, Oberhoff C, et al: Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16:64-69, 2005
9. von Minckwitz G, Kümmel S, Vogel P, et al: Intensified neoadjuvant chemotherapy in earlyresponding breast cancer: Phase III randomized GeparTrio study. J Natl Cancer Inst 100:552-562, 2008
10. von Minckwitz G, Kümmel S, Vogel P, et al: Neoadjuvant vinorelbine-capecitabine versus docetaxeldoxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542-551, 2008
11. von Minckwitz G, Untch M, Nüesch E, et al: Impact of treatment characteristics on response of different breast cancer phenotypes: Pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145-156, 2011
12. von Minckwitz G, Untch M, Blohmer JU, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804, 2012
13. von Minckwitz G, Blohmer JU, Raab G, et al: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 16:56-63, 2005
14. Costa SD, Loibl S, Kaufmann M, et al: Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: A secondary analysis of the GeparTrio trial data. J Clin Oncol 28:83-91, 2010
15. von Minckwitz G, Zahm MD, Eidtmann H, et al: Zoledronic acid (ZOL) as add on therapy in patients with tumor residuals after neoadjuvant chemotherapy for primary breast cancer: First interim safety analysis of the NATAN study (GBG 36). Presented at the American Society of Clinical Oncology Breast Symposium, San Francisco, CA, October 8-10, 2009 (abstr 216)
16. Remmele W, Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189:862-866, 1993
17. Elston EW, Ellis IO: Method for grading breast cancer. J Clin Pathol 46:189-190, 1993
18. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007
19. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
20. Eiermann W, Pienkowski T, Crown J, et al: Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 Trial. J Clin Oncol 29: 3877-3884, 2011
21. von Minckwitz G, Müller B, Blohmer JU, et al: Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. J Clin Oncol 30:54s, 2012 (suppl; abstr 1023).
22. von Minckwitz G, Raab G, Caputo A, et al: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685, 2005
23. von Minckwitz G, Rezai M, Loibl S, et al: Capecitabine in addition to anthracycline/taxanebased neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study. J Clin Oncol 28:2015-2023, 2010